Zusammenfassung
Hintergrund
Der Barrett-Ösophagus wird als entscheidende Ursprungsläsion für das Adenokarzinom am ösophagogastralen Übergang (AEG) angesehen.
Weitgehend unklar ist allerdings nach wie vor, welche Faktoren, Einwirkungen und Abläufe für die Karzinogenese verantwortlich sind.
Fragestellung
In dieser Übersichtsarbeit sollen v. a. die Bedeutung epidemiologischer, genetischer und immunologischer Faktoren sowie der Einfluss eines hierdurch teilweise veränderten Mikromilieus als initiierende Faktoren erörtert werden.
Ergebnisse
Veränderungen in Mikrobiom und Genstruktur (z. B. durch Verlust von TP53 und p16) können eine Nische von Stammzellen am ösophagogastralen Übergang (die z. B. in Mäusen LGR5, CCK2R und CAR4 exprimieren) bilden, in der vermehrte Zellteilung sowie eine maligne Entartung begünstigt wird. Dabei könnten spezifische Stammzellen, die wahrscheinlich aus Drüsen im Bereich der Kardia im Magen entstehen − als Ursprung für die maligne Transformation sowie in Abhängigkeit von ihrem Differenzierungspotenzial für die Tumorentstehung ausschlaggebend sein. Aktuelle Studien deuten darauf hin, dass das metaplastische Epithel nicht im Ösophagus, sondern in der Kardia entsteht, von wo Stammzellen (im weiteren Verlauf) in den Ösophagus expandieren.
Schlussfolgerungen
Ein besseres Verständnis dieser Mechanismen kann zu einer besseren Früherkennung, Prävention und schlussendlich auch Therapie der AEG führen.
Abstract
Background
Barrett esophagus is defined as the decisive precursor lesion for the development of adenocarcinoma of the esophagogastric junction (AEGJ); however, little is known about the risk factors and mechanisms which are responsible for the carcinogenesis.
Objective
In this review the importance of epidemiological, genetic and immunological factors as well as the impact of the microenvironment as initiating factors in the development of AEGJ are discussed.
Results
Alterations in genomic structure (e.g. due to the loss of TP53 or p16) and the microbiome could lead to the development of a niche of stem cells in the gastroesophageal junction (e.g. labeled by LGR5, CCK2R and CAR4 in mice) that encourage a faster cell division and malignant transformation. Specific stem cells, probably originating from cardiac glands of the stomach, could be responsible for the malignant transformation and, depending on the differentiation pattern, could be crucial for the carcinogenesis. The results of current studies indicate that the metaplastic epithelium arises not in the esophagus but in the cardia and in the further course the stem cells expand from there into the esophagus.
Conclusion
A better understanding of the mechanisms by which normal squamous epithelium progresses to early stage invasive cancer will help formulate rational surveillance guidelines and allow resources to be diverted away from patients at low risk of malignancy.
Literatur
Verwendete Literatur
Corley DA et al (2009) Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994–2006. Gut 58(2):182–188
Brown LM, Devesa SS, Chow WH (2008) Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 100(16):1184–1187
Jemal A et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58(2):71–96
Barrett NR (1950) Chronic peptic ulcer of the oesophagus and “oesophagitis”. Br J Surg 38(150):175–182
Fan X, Snyder N (2009) Prevalence of Barrett’s esophagus in patients with or without GERD symptoms: role of race, age, and gender. Dig Dis Sci 54(3):572–577
Meves V, Behrens A, Pohl J (2015) Diagnostics and early diagnosis of esophageal cancer. Viszeralmedizin 31(5):315–318
Sundelof M, Lagergren J, Ye W (2008) Patient demographics and lifestyle factors influencing long-term survival of oesophageal cancer and gastric cardia cancer in a nationwide study in Sweden. Eur J Cancer 44(11):1566–1571
Inadomi JM et al (2003) Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 138(3):176–186
Hur C et al (2013) Trends in esophageal adenocarcinoma incidence and mortality. Cancer 119(6):1149–1158
Mariette C et al (2003) Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 97(7):1616–1623
Pennathur A et al (2009) Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg 87(4):1048–1054 (discussion 1054–1055)
Fitzgerald RC et al (2013) British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 63(1):7–42. https://doi.org/10.1136/gutjnl-2013-305372
Shaheen N, Ransohoff DF (2002) Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA 287(15):1972–1981
Falk GW (2002) Barrett’s esophagus. Gastroenterology 122(6):1569–1591
American Gastroenterological Association (2011) American Gastroenterological Association medical position statement on the management of Barrett’s esophagus. Gastroenterology 140(3):1084–1091
Verbeek RE et al (2014) Surveillance of Barrett’s esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am J Gastroenterology 109(8):1215–1222
Shaheen NJ, Richter JE (2009) Barrett’s oesophagus. Lancet 373(9666):850–861
Anaparthy R et al (2013) Association between length of Barrett’s esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol 11(11):1430–1436
Whitson MJ, Falk GW (2015) Predictors of progression to high-grade dysplasia or adenocarcinoma in Barrett’s esophagus. Gastroenterol Clin North Am 44(2):299–315
Jopling C, Boue S, Izpisua Belmonte JC (2011) Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nat Rev Mol Cell Biol 12(2):79–89
Wang X et al (2011) Residual embryonic cells as precursors of a Barrett’s-like metaplasia. Cell 145(7):1023–1035
Leedham SJ et al (2008) Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett’s oesophagus. Gut 57(8):1041–1048
van Nieuwenhove Y, Destordeur H, Willems G (2001) Spatial distribution and cell kinetics of the glands in the human esophageal mucosa. Eur J Morphol 39(3):163–168
Jiang M et al (2017) Transitional basal cells at the squamous-columnar junction generate Barrett’s oesophagus. Nature 550(7677):529–533
Quante M et al (2012) Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 21(1):36–51. https://doi.org/10.1016/j.ccr.2011.12.004
Nakanishi Y et al (2007) Distribution and significance of the oesophageal and gastric cardiac mucosae: a study of 131 operation specimens. Histopathology 51(4):515–519
Barbera M, Fitzgerald RC (2010) Cellular origin of Barrett’s metaplasia and oesophageal stem cells. Biochem Soc Trans 38(2):370–373
Dulak AM et al (2012) Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 72(17):4383–4393
Yamamoto Y et al (2016) Mutational spectrum of Barrett’s stem cells suggests paths to initiation of a precancerous lesion. Nat Commun 7:10380
Sato T, Clevers H (2013) Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science 340(6137):1190–1194
Cancer Genome Atlas Research Network (2017) Integrated genomic characterization of oesophageal carcinoma. Nature 541(7636):169–175
Galipeau PC et al (2007) NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4(2):e67
Rubenstein JH, Thrift AP (2015) Risk factors and populations at risk: selection of patients for screening for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol 29(1):41–50
Robertson EV et al (2013) Central obesity in asymptomatic volunteers is associated with increased intrasphincteric acid reflux and lengthening of the cardiac mucosa. Gastroenterology 145(4):730–739
Anderson LA et al (2008) Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study. Gut 57(6):734–739
Anderson LA et al (2007) Risk factors for Barrett’s oesophagus and oesophageal adenocarcinoma: results from the FINBAR study. World J Gastroenterol 13(10):1585–1594
Yates M et al (2014) Body mass index, smoking, and alcohol and risks of Barrett’s esophagus and esophageal adenocarcinoma: a UK prospective cohort study. Dig Dis Sci 59(7):1552–1559
El-Serag H (2008) The association between obesity and GERD: a review of the epidemiological evidence. Dig Dis Sci 53(9):2307–2312
Kabat GC, Ng SK, Wynder EL (1993) Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control 4(2):123–132
Gall A et al (2015) Bacterial Composition of the Human Upper Gastrointestinal Tract Microbiome Is Dynamic and Associated with Genomic Instability in a Barrett’s Esophagus Cohort. PLoS ONE 10(6):e129055
Kaakoush NO et al (2015) Is Campylobacter to esophageal adenocarcinoma as Helicobacter is to gastric adenocarcinoma? Trends Microbiol 23(8):455–462
Amir I et al (2014) Gastric microbiota is altered in oesophagitis and Barrett’s oesophagus and further modified by proton pump inhibitors. Environ Microbiol 16(9):2905–2914
Goodman AL, Gordon JI (2010) Our unindicted coconspirators: human metabolism from a microbial perspective. Cell Metab 12(2):111–116
Pei Z et al (2004) Bacterial biota in the human distal esophagus. Proc Natl Acad Sci U S A 101(12):4250–4255
Elliott DRF et al (2017) A non-endoscopic device to sample the oesophageal microbiota: a case-control study. Lancet Gastroenterol Hepatol 2(1):32–42
Munch N et al (2019) High-fat diet accelerates carcinogenesis in a mouse model of Barrett’s esophagus via IL8 and alterations to the gut microbiome. Gastroenterology 157(2):492–506.e2. https://doi.org/10.1053/j.gastro.2019.04.013
Ajayi TA et al (2018) Barrett’s esophagus and esophageal cancer: links to microbes and the microbiome. PLoS Pathog 14(12):e1007384
Yamamura K et al (2016) Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res 22(22):5574–5581
Winter JW et al (2007) N‑nitrosamine generation from ingested nitrate via nitric oxide in subjects with and without gastroesophageal reflux. Gastroenterology 133(1):164–174
Bockler R, Meyer H, Schlag P (1983) An experimental study on bacterial colonization, nitrite and nitrosamine production in the operated stomach. J Cancer Res Clin Oncol 105(1):62–66
Brusselaers N, Engstrand L, Lagergren J (2018) Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol 53:172–177
Chow WH et al (1998) An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 58(4):588–590
Thrift AP et al (2012) Helicobacter pylori infection and the risks of Barrett’s oesophagus: a population-based case-control study. Int J Cancer 130(10):2407–2416
Kinnebrew MA, Pamer EG (2012) Innate immune signaling in defense against intestinal microbes. Immunol Rev 245(1):113–131
Grivennikov SI et al (2012) Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491(7423):254–258
Fitzgerald RC et al (2002) Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50(4):451–459
Masclee GM et al (2015) NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett’s oesophagus: a population-based case-control study. BMJ Open 5(1):e6640
Chiba N et al (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112(6):1798–1810
Hvid-Jensen F et al (2014) Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett’s oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther 39(9):984–991
Koop H, Klein M, Arnold R (1990) Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther 4(2):131–138
Prasad GA et al (2008) Utility of biomarkers in prediction of response to ablative therapy in Barrett’s esophagus. Gastroenterology 135(2):370–379
Buas MF et al (2014) Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis 35(12):2740–2747. https://doi.org/10.1093/carcin/bgu207
Kastelein F et al (2013) Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus. Gut 62(12):1676–1683
Klump B et al (1998) Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett’s esophagus. Gastroenterology 115(6):1381–1386
Wild CP, Hardie LJ (2003) Reflux, Barrett’s oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer 3(9):676–684
Maag JLV et al (2017) Novel aberrations uncovered in Barrett’s esophagus and esophageal adenocarcinoma using whole transcriptome sequencing. Mol Cancer Res 15(11):1558–1569
Zhao J et al (2007) Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping. Mol Cell Proteomics 6(6):987–999
Wiethaler M et al (2019) BarrettNET—a prospective registry for risk estimation of patients with Barrett’s esophagus to progress to adenocarcinoma. Dis Esophagus 32(8):doz24. https://doi.org/10.1093/dote/doz024
Quante M, Graham TA, Jansen M (2018) Insights into the pathophysiology of esophageal adenocarcinoma. Gastroenterology 154(2):406–420. https://doi.org/10.1053/j.gastro.2017.09.046
Weiterführende Literatur
Souza RF, Krishnan K, Spechler SJ (2008) Acid, bile, and CDX: the ABCs of making Barrett’s metaplasia. Am J Physiol Gastrointest Liver Physiol 295(2):G211–G218
Xian W et al (2019) The cellular origin of Barrett’s esophagus and its stem cells. Adv Exp Med Biol 1123:55–69
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Interessenkonflikt
L. Liotta und M. Quante geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Rights and permissions
About this article
Cite this article
Liotta, L., Quante, M. Pathophysiologie des Adenokarzinoms am ösophagogastralen Übergang (AEG). Onkologe 25, 1055–1064 (2019). https://doi.org/10.1007/s00761-019-00666-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-019-00666-9